Our History

Orphazyme was founded in Denmark in 2009 on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature.

We translated this scientific discovery into late-stage clinical trials of our investigational drug candidate, arimoclomol, with the aim of developing new treatment options for people with neurodegenerative diseases, such as Niemann-Pick disease type-C (NPC).

In May 2022, substantially all of Orphazyme’s assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc.

Our Core Values

COURAGE

PERSEVERANCE

CARE

INTEGRITY

Leadership Team
Anders Vadsholt, MBA

Anders Vadsholt, MBA

Chief Executive Officer & Chief Financial Officer

  • MBA from Melbourne University, MSc in Commercial Law and Economics from Copenhagen Business School
  • Joined in 2016
  • 25 years' biotech and corporate finance experience
  • Previously at Topotarget, Bankinvest Biomedical Venture, and Carnegie Investment Banking
Board of Directors

Michael Hove

Chairman

  • Member since: 2023
  • Born 1971, Danish nationality
  • Holds a bachelor in economic from 1995 from Copenhagen Business School.

Jakob Bendtsen

Board Member

  • Member since: 2023
  • Born 1978, Danish nationality
  • MSc in Business Administration and Auditing from Copenhagen Business School.

Jakob Have

Board Member

  • Member since: 2023
  • Born 1981, Danish nationality
  • MSc in Business Administration and Auditing from Copenhagen Business School.